Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) Files An 8-K Unregistered Sales of Equity SecuritiesItem 3.02.
On August 1, 2017, the Company sold to an unaffiliated investor 5.0 million shares of its common stock at a price of $0.20 per share and issued to such investor 2.5 million Class D Warrants exercisable at $0.23 per share for a period of two years, and 2.5 million Class D Warrants exercisable at $0.30 per share for a period of two years, for an aggregate of $1.0 million.
The securities were issued to the exemption from the registration requirements afforded by Section 4(a)(2) and Regulation D of the Securities Act.
About Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO)
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid tumor cancers. The Company’s lead product, DCVax-L, is in an ongoing Phase III trial for diagnosed Glioblastome multiforme (GBM), with over 60 trial sites. Its second product, DCVax-Direct, is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct. The Company’s platform technology, DCVax, uses activated dendritic cells to mobilize a patient’s own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer.
